In October 2014, Europe’s medicines regulator, the European Medicines Agency (EMA), scrapped proposed restrictions on the sharing of clinical trial data that it considers for medicine approval. Those restrictions would have made the independent scrutiny of data almost impossible. Supporters of AllTrials — a campaign launched in January 2013 which calls for all past and present clinical trials to be registered and their results reported — welcomed the move as a big step forward for clinical trial transparency in Europe. Unfortunately, the EMA has not gone far enough: pharmaceutical companies will still be permitted to redact their clinical trial data selectively, putting the transparency of the new policy at risk. The EMA needs to heed the many calls to fix this much anticipated policy on the sharing of clinical trial data in order to promote transparency of the medicines approval process.